Home/Pipeline/Mutant plasmid cDNA for A1AR

Mutant plasmid cDNA for A1AR

Cancer

PreclinicalActive

Key Facts

Indication

Cancer

Phase

Preclinical

Status

Active

Company

Endacea

About Endacea

Endacea is a long-standing, privately-held biotech firm leveraging deep expertise in A1 adenosine receptor biology to develop novel therapeutics. Its pipeline features two lead preclinical assets: L-97-1, a 'best-in-class' A1 antagonist for sepsis and acute renal failure, and a mutant plasmid cDNA A1 receptor gene therapy for cancer. The company is led by its founder, Dr. Constance Neely Wilson, and seeks partnerships and investment to advance its virtual R&D efforts towards clinical trials.

View full company profile

Therapeutic Areas

Oncology Critical Care Nephrology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active